A Unique Materials Platform for a Paradigm Shift in Cell Screening
What We Do
Turning Adherent Cells into Liquid Reagents
Our SemaCyte® assaying microcarriers function as ultra-miniaturized wells suspended in liquid. These flat substrates carry small colonies of adherent cells and are magnetically steerable.
Seamless Integration for Better and Faster Data
We accelerate workflows, miniaturize assays, and multiplex cell types to drive 10x gains in drug screening. The SemaCyte® platform enhances existing methodologies and enables new ones.
Who We Are
Interfacing microchip-inspired hardware with the complex world of cell biology
Semarion leverages microfabrication technology to build smart materials and develop novel cell assaying applications for unmet screening needs.
News
Featured
Partnering
27th July 2021
University Enterprise Zone – Semarion as case study for Connect Health Tech
As a spin-out company from the University of Cambridge, Semarion and its co-founders, Jeroen & Tarun, have gained support from a variety of networks, such as the NanoDTC, the Cambridge CRUK Early Detection Programme, the...
Read More
Business
22nd February 2022
Semarion raises £2.14m seed funding to commercialise cell assaying platform
Funding will support recruitment, commercial partnerships, and further development of Semarion’s SemaCyte cell assaying platform, which turns adherent cells into liquid reagents to enable novel drug screening methodolo...
Read More
Our Partners
